We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Life Settlement Assets Plc | LSE:LSAA | London | Ordinary Share | GB00BF1Q4B05 | ORD SHS USD0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.70 | 1.60 | 1.80 | 1.70 | 1.70 | 1.70 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 8.85M | 599k | 0.0120 | 141.67 | 84.71M |
From Apr 2019 to Apr 2024
TIDMLSAA TIDMLSAB TIDMLSAD TIDMLSAE
RNS Number : 4012C
Life Settlement Assets PLC
28 September 2018
Life Settlement Assets Plc ("LSA" or the "Company")
Interim Financial Report
For the period ended 30 June 2018
Life Settlement Assets ("LSA" or the "Company") a closed-ended investment company which supports and manages portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the United States, is pleased to announce its financial results for the period of incorporation on 16 August 2017 to 30 June 2018.
The Company was admitted to trading on the Specialist Fund Segment of the London Stock Exchange on 26 March 2018 and was formed for the purposes of continuing the business of the Acheron Portfolio Corporation (Luxembourg) S.A (the "Predecessor Company"). The Predecessor Company delisted from the Luxembourg Stock Exchange on 6 March 2018.
For comparison reasons only in the commentary below, results from the unaudited interim consolidated financial statements for the six months ended 30 June 2017 have been taken from the Predecessor Company.
Key Highlights
-- Total collected maturities increased 35% to USD 20.3m (HY2017: USD 15.0m), reflecting higher HIV maturities in the period
- Class A delivered collected maturities of USD 13.7m (HY2017: USD 10.1m)
- Class B delivered collected maturities of USD 3.0m (HY2017: USD 1.3m)
- Class D delivered collected maturities of USD 1.7m (HY2017: USD 2.8m)
- Class E delivered collected maturities of USD 1.8m (HY2017: USD 0.8m)
-- Loss before tax of USD 4.9m (HY2017: profit of USD 130,596). The decrease is a result of lower non-HIV, elderly maturities in the period, which had a notable impact on performance due to the concentration of the portfolio in a relatively small number of large policies in this segment
-- The level of maturities in the HIV segment of the portfolios of the Predecessor Company in the 2017 financial year allowed a distribution of USD 11.5m to A, D and E Share Classes just prior to the listing on the London Stock Exchange.
Jean Medernach, Chairman, said: "These are our maiden interim financial results since admission to trading on the Specialist Fund Segment of the London Stock Exchange. Our listing was a milestone moment in the Company's history, which gives us access to a wider investor base. While our results impacted by the elderly segment, we significantly outperformed in the HIV segment. Furthermore, the Predecessor Company was able to make USD 11.5m distributions across to shareholders of the A, D and E Classes immediately prior to the admission to trading of the new shares. Acheron Capital, our Investment Manager continues to focus on generating long-term returns for our shareholders by diversifying our portfolio and acquiring additional fractional policies at a deep discount, transforming them in to wholly owned policies."
For further information, please contact:
Stockdale Securities Limited (Financial Adviser and Broker)
Robert Finlay / Rose Ramsden
020 7601 6115
George Bayer / Kerry Higgins
Maitland Administration Services Limited
Company Secretary
Tel: 01245 209780
TB Cardew (Financial PR)
Shan Shan Willenbrock/Emma Crawshaw
020 7930 0777
Chairman's Statement
I am pleased to present our maiden interim financial results since the Company was incorporated on 16 August 2017 and subsequently admitted to the Specialist Fund Segment of the London Stock Exchange on 26 March 2018
Life Settlement Assets' investment objective is to generate long-term returns for investors by investing in the life settlement market. We seek to achieve this through each of our separate Share Classes:
-- Share Class A
Share Class A invests in life insurance policies acquired from special or "distressed" situations, with exposure to both HIV (average age mid to late 50s) and elderly insureds (average age mid to late 80s). It is widely diversified with circa 4,700 underlying policies. Class A has exposure to fractional policies.
-- Share Class B
Share Class B invests in life insurance policies exposed only to elderly insureds (average age mid to late 80s). Class B has exposure to fractional policies.
-- Share Class D and E
Both these Share Classes invest in separate portfolios comprising predominantly fractional policies with exposure to both HIV or elderly insureds, where the A and/or B Share Classes are already fractional owners.
In the period under review, but just prior to the Company's admission to the Specialist Fund Segment of the London Stock Exchange, an USD 11.5m distribution was made across A, D and E Share Classes which resulted from the maturities in the portfolios of the Predecessor Company in the 2017 financial year.
Performance Analysis by Share Class is provided in the tables below. Comparative figures have been provided from the unaudited interim consolidated financial statements for the six months ended 30 June 2017 of the Predecessor Company.
Share Class A net asset value ("NAV") per share increased to USD 2.03 during the period. Class A experienced higher levels of maturities compared to the previous year in the HIV segment. However, the elderly segment, despite the advanced ages, has underperformed due to the lack of any large size policies maturing which in turn has affected cash flow and performance. The current estimated actual to expected ratio of maturities in Class A is c.130% for the HIV segment and 30% for the elderly segment.
Share Class B NAV per share increased to USD 1.23. There were no large size policies maturing in the period despite the insureds' increasingly advanced ages. Given the lack of policy diversification, this is not an unusual outcome and previous years have shown that this period of low maturities will be followed by a period of renewed maturities that will increase liquidity.
Share Class D delivered NAV per share of USD 1.6. Share Class E delivered NAV per share of USD 4.56. Class D and E are made of fractional policies and have a relatively high concentration on a few lives.
Fractional policies are single life insurance policies initially purchased by multiple investors, each of whom acquire a fractional interest. They have a higher expected level of return and tend to be acquired at a deep discount to the fair value of the policies.
Share Class A
Hot Features
Premium
USD HY2018 HY2017
Collected maturities 13,698,530 10,117,832
----------- -----------
Net income from
portfolio 140,957 3,287,835
----------- -----------
Profit (Loss) before
tax -3,204,383 918,470
----------- -----------
NAV per share 2.03 1.93
----------- -----------
Share Class B
Class B
USD HY2018 HY2017
---------- -----------
Collected maturities 2,988,505 1,258,316
---------- -----------
Net income from
portfolio -275,367 -1,021,226
---------- -----------
Profit (Loss) before
tax -676,908 -1,304,447
---------- -----------
NAV per share 1.23 1.11
---------- -----------
Share Class D and E
Class D
USD HY2018 HY2017
----------- ----------
Collected maturities 1,747,326 2,814,184
----------- ----------
Net income from portfolio -733,013 1,401,622
----------- ----------
Profit (Loss) before
tax -1,183,972 1,117,425
----------- ----------
NAV per share 1.16 1.83
----------- ----------
Class E
USD HY2018 HY2017
---------- ---------
Collected maturities 1,844,040 844,400
---------- ---------
Net income from portfolio 142,323 -404,978
---------- ---------
Profit (Loss) before
tax -159,025 -600,851
---------- ---------
NAV per share 4.56 5.14
---------- ---------
Life Settlement Assets remains focused on maximising performance and distributing realised profit derived from its portfolio to its shareholders. While cash flow for the period under review has been impacted, our unique, seasoned portfolio with leading Actual to Expected performance, continues to deliver long-term positive cash flow. In order to address performance volatility, we will continue to acquire additional fractional policies at a deep discount to the fair value of the policies, transforming them into wholly owned policies. This will both diversify the portfolio with a larger number of policies to generate a more stable cash flow and further shareholder value. The US market remains supportive of the life settlements industry, both through its aging population and changing US public policies, which are resulting in a restructuring of the industry.
Principal risks and uncertainties for the remaining six months of the financial year
The Company's results for the first full financial year will depend on maturities declared and collected until year end. Exposure to a small number of large face value policies implies that there is likely to be material volatility in the full year financial results. Going forward, the Board will focus on generating further shareholder value through the acquisition of additional fractional policies at a deep discount to fair value of the policies, and progressively transforming them in to wholly owned policies.
The Board believes it is in the interests of Shareholders to maintain an appropriate robust capital structure and only make distributions to shareholders when collected maturities are sufficient and in line with the actuary's models. The Board also continues to assess the appropriate required reserves for premium payments and other operational costs.
For a detailed description of the Company's risks, please refer to note 5 of the financial statements.
The Investment Manager's Report
The principal activities of the Company are to support and manage portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating in the United States. The Company acquires both individual life insurance policies and portfolios of such policies via either the secondary market, liquidation, bankruptcies or private placements. The life settlement market enables people to sell their life insurance policies to investors at a higher cash value than they would otherwise receive from insurance companies. An investor acquiring the life insurance policy will continue to pay the premiums until the death of the insured. The insurance company will then pay the face value of the life insurance policy to the investor.
On admission to the Specialist Fund Segment of the London Stock Exchange, the Company acquired the Predecessor Company Portfolio (all the assets of the Predecessor Company) by acquiring the entire beneficial interest of four Trusts through which the life settlement policies comprising the Predecessor Company Portfolio are held. Following the completion of the acquisition, the Company allocated beneficial ownership of the Acheron Portfolio Trust to the A Ordinary Shares, the Lorenzo Tonti 2006 Portfolio Trust to the B Ordinary Shares, Avernus Portfolio Trust to the D Ordinary Shares, and the Styx Portfolio Trust to the E Ordinary Shares.
Acheron Capital Limited ("Acheron Capital" or the "Investment Manger") is responsible for devising and modelling the investment strategy of the Company's trusts. Founded in 2005, Acheron Capital is a London based independent investment manager authorised and regulated by the FCA, that focuses on niche investment strategies uncorrelated to the traditional financial markets.
The Investment Manager has:
-- An internally developed pricing policy and portfolio valuation methodologies -- Proven actuarial model as evidenced by industry leading Actual to Expected ratios
-- Delivered an internal rate of return of between 6 and 7% to the original investor in Share Class A based on the change in NAV and distributions*
*The internal rate of return refers to the Predecessor Company. The original investor would be invested from the period of 30 September 2007 to 31 December 2017.
The Life Settlement Market
The life settlement industry in the United States during the first six months of 2018 was marked by the Tax Cuts and Jobs Act 2017 (TCJA). This is a boost to the market as it brings feasibility to policyholders to sell their policy. Previously, tax basis calculation for people selling their insurance policies and those surrendering was different: the former could deduct from sales proceeds past cumulative Cost of Insurance (COI), while the latter imputed past cumulative premium payments. Because information on past COI was difficult and sometimes impossible to obtain, many people lapsed or surrendered a policy. TCJA makes the basis calculation for both approaches identical, resulting in the abolition of a tax incentive to surrender rather than to sell a policy. This measure will support the supply of life settlements. Meanwhile, efforts have been made to streamline the policy selling process with the help of electronic health records and short-form underwriting. These approaches have the potential to transact a much larger number of policies in a shorter time and thus make transactions more accessible for millions of people.
New bankruptcies and liquidation have emerged as the industry continues to restructure. The investment Manager continues to follow these new offerings, as well as other market supply sources, closely.
Portfolio
The overall portfolio is subdivided into portfolios exposed to either HIV-positive policy holders or non-HIV positive policy holders. The following table provides information on the Companies' policies by Share Class and by exposure to HIV and non-HIV positive insureds in the period under review.
Share Class A HIV Non-HIV Total
Number of policies 4 443 221 4664
------------ ------------ ------------
Total face value 361 479 516 100 984 455 462 463 971
------------ ------------ ------------
Valuation 41 744 823 25 464 353 67 209 176
------------ ------------ ------------
Percentage of
face 11.5% 25.2% 14.53%
------------ ------------ ------------
Share Class B
------------ ------------ ------------
Number of policies N/A 117 117
------------ ------------ ------------
Total face value N/A 59 665 653 59 665 653
------------ ------------ ------------
Valuation N/A 12 814 403 12 814 403
------------ ------------ ------------
Percentage of
face N/A 21.5% 21.5%
------------ ------------ ------------
Share Class D
------------ ------------ ------------
Number of policies 379 100 479
------------ ------------ ------------
Total face value 16 466 988 26 630 313 43 097 301
------------ ------------ ------------
Valuation 2 338 848 7 352 953 9 691 800
------------ ------------ ------------
Percentage of
face 14.2% 27.6% 22.45%
------------ ------------ ------------
Share Class E
------------ ------------ ------------
Number of policies 167 73 240
------------ ------------ ------------
Total face value 6 361 256 16 015 783 22 377 039
------------ ------------ ------------
Valuation 947 705 4 501 867 5 449 572
------------ ------------ ------------
Percentage of
face 14.9% 28.1% 24.35%
------------ ------------ ------------
In May 2018, a small portfolio of fractional policies, to which the trusts were already overwhelmingly exposed, was added. The portfolio added exposures to 91 policies in which 71 are HIV policies and 20 are Non-HIV policies. It has a total face value of $ 4.7 million. 75 policies with a coverage of $ 4.3 million were assigned to the portfolio held by Acheron Portfolio Trust. The remaining 19 policies with a face value of $ 0.4 million were allocated to Lorenzo Tonti Trust, Avernus Portfolio Trust and Styx Portfolio Trust.
Declared maturity details can be seen in the table below.
Class A Class B Class D Class E
HIV Maturities
(USD) 4 704 882 N/A 258 869 192 601
---------- ---------- -------- --------
Non-HIV Maturities
(USD) 3 543 849 2 216 862 577 496 617 148
---------- ---------- -------- --------
The losses incurred are mainly the result of premiums exceeding maturities together with normal change in policy values. More precisely, while the HIV portfolio has performed well and above expectations, the non-HIV portfolio (elderly) has underperformed. This is largely, but not exclusively, due to the fact that the portfolio is overwhelmingly concentrated in three large policies of an advanced age, which did not mature during the period. Volatility in the maturity of such a limited number of policies is to be expected.
At 30 June 2018, Share Class A had a NAV of $ 2.0299 per share. Share Class B had a NAV of $ 1.2283. Share Class D and E had a NAV of $ 1.1561 and $ 4.5559 respectively. NAV and share price performance history can be seen in the table below.
Class A Year Apr May Jun YTD
Total NAV
Return 2018 0.24% 0.14% -0.52% -0.14%
------ ------ ------ ------- -------
Share Price
Performance 2018 0.00% 5.17% -1.64% 3.45%
------ ------ ------ ------- -------
Class B Year Apr May Jun YTD
Total NAV
Return 2018 0.24% 0.14% -0.52% -0.14%
------ ------ ------ ------- -------
Share Price
Performance 2018 0.00% 5.17% -1.64% 3.45%
------ ------ ------ ------- -------
Class D Year Apr May Jun YTD
Total NAV
Return 2018 -1.47% -0.80% -1.28% -3.51%
------ ------- ------- ------- -------
Share Price
Performance 2018 18.18% 0.00% 0.00% 18.18%
------ ------- ------- ------- -------
Class E Year Apr May Jun YTD
Total NAV
Return 2018 -1.60% -0.40% 3.51% 1.45%
------ ------- ------- ------ -------
Share Price
Performance 2018 0.00% 12.90% 0.00% 12.90%
------ ------- ------- ------ -------
Portfolio Composition
Further information on the composition of the portfolio of each Share Class as at 30 June 2018 can be found on our website https://www.lsaplc.com/investor-relations/reports-company-literature/
Life Settlement Assets Plc
Interim consolidated statement of financial position as
at 30 June 2018
______________________________________________________________
Notes 30/06/2018
USD
ASSETS
Non-current assets
Financial assets at fair value through
profit and loss
- Life settlement investments 6 95 530 397
Maturities Receivables 6 562 863
9 102 093 260
Current assets
Premiums paid in advance 7 12 887 408
Other receivables and prepayments 268 258
Cash and cash equivalents 8 19 323 043
32 478 708
Total Assets 134 571 968
=============
LIABILITIES
Capital and reserves
Share capital 10 710 689
Share premium 133 013 486
Retained Earnings -4 900 648
128 823 527
Current liabilities
Trade and other payables 3 849 470
Tax liabilities 17 745 310
Other liabilities 11 1 153 661
5 748 441
Total Liabilities 134 571 968
=============
Life Settlement Assets Plc
Interim consolidated statement of profit or loss and other comprehensive
income
for the period ended 30 June 2018
_____________________________________________________________
Notes Revenue Capital Total
return return
USD USD USD
Income from life-settlement portfolios 12
Maturities - 20 278 400 20 278 400
Acquisition cost of maturities - -1 094 831 -1 094 831
-11 285 -11 285
Premiums paid - 217 217
Fair value adjustments - -8 623 451 -8 623 451
__________ __________ __________
Net income from life-settlement portfolio - - 725 099 - 725 099
Other operating income 394 557 - 394 557
Operating expenses 13 -4 167 871 - -4 167 871
Finance income
Interest income 7 630 - 7 630
Other income from matured policies 14 274 729 - 274 729
__________ __________ __________
282 359 - 282 359
Finance costs
Interest expenses 15 - 632 595 - - 632 595
Net foreign exchange loss - 51 802 - - 51 802
__________ __________ __________
- 684 397 - - 684 397
Profit (Loss) before tax -4 175 352 - 725 099 -4 900 451
Income tax expenses - 197 - - 197
__________ __________ __________
Profit (Loss) for the period -4 175 548 - 725 099 -4 900 648
=========== =========== ===========
Other comprehensive income - - -
Total comprehensive income for the
period -4 175 548 - 725 099 -4 900 648
=========== =========== ===========
Total comprehensive income attributable
to the owners of the Company -4 175 548 - 725 099 -4 900 648
=========== =========== ===========
Basic and diluted profit per share
class A 19 -0,133
- numerator class A -3 204 579
Basic and diluted profit per share
class B -0,087
- numerator class B - 676 908
Basic and diluted profit per share
class D -0,186
- numerator class D - 918 231
Basic and diluted profit per share
class E -0,110
- numerator class E - 100 929
Life Settlement Assets Limited
Interim consolidated statement of changes in equity for the period ended
30 June 2018
________________________________________________________________
Share Share premium Legal Retained Total
capital reserve earnings
USD USD USD USD USD
Balance as at 16 August - - - - -
2017
Incorporation 66 988 - - - 66 988
Capital increase 26 March 133 013 133 724
2018 710 689 486 - - 175
Redemption of redeemable
shares - 66 988 - - - - 66 988
-4 900
Loss for the period - - - 648 -4 900 648
133 013 -4 900 128 823
Balance as at 30 June 2018 710 689 486 - 648 527
========== ============== =========== =========== =============
Life Settlement Assets Plc
Interim consolitated cash flow statement for the period
ended 30 June 2018
_____________________________________________________
30/06/2018
USD
Cash flow from operating activities
-4 900
Profit (Loss) for the period 648
Non cash adjustments:
- non cash movement on portfolios 8 856 669
Cash flows from (used) in operations before working
capital changes 3 956 021
Changes in premiums paid in advance 1 001 035
Changes in other receivables and prepayments - 231 777
-4 561
Changes in trade and other payables 461
Changes in tax payables - 11 785
Net cash flows from (used) in operating activities 152 034
Cash flow from investing activities
Net investment in life-settlement portfolios 442 557
Net cash flows from (used) in investing activities 442 557
Cash flow from financing activities
18 883
Cash proceeds from issuing shares 524
Cash on policies - 155 072
Repayment share premium -
18 728
Net cash flows from (used) financing activities 452
19 323
NET CHANGES IN CASH AND CASH EQUIVALENTS 043
Cash and cash equivalents
At the beginning of the period -
19 323
At the end of the period 043
===========
Note 1 General information
1.1 Legal aspects
Life Settlement Assets ("Life Settlement Assets" or the "Company") is a public company limited by shares and an investment company under section 833 of the Companies Act 2006. It was incorporated in England and Wales on 16 August 2017. The registered office of the Company is 115 Park Street, 4th Floor, London W1K 7AP.
The Company currently has four classes of Ordinary Shares in issue, namely A, B, D and E, each of which principally participates in a separate portfolio of life settlement assets and associated liabilities, which were acquired from Acheron Portfolio Corporation (Luxembourg) SA (APC or the Predecessor Company) on 26 March 2018.
On that date, the Company entered into an Acquisition agreement with the Predecessor Company. Following the agreement, all assets and liabilities of APC have been transferred to the Company as an in specie subscription for ordinary shares. More specifically:
- 100% of the interest in the Acheron Portfolio Trust has been attributed to the A ordinary shares;
- 100% of the interest in the Lorenzo Tonti 2006 Portfolio Trust has been attributed to the B ordinary shares;
- 100% of the interest in the Avernus Portfolio Trust has been attributed to the D ordinary shares;
- 100% of the interest in the Styx Portfolio Trust has been attributed to the E ordinary shares;
- Any cash and other net assets have been recorded in the books of the Company as being attributable to the class of ordinary shares which corresponds to the existing class of shares in APC to which such cash and other net assets are attributable.
Net assets acquired from the Predecessor Company have been valued for the purpose of Section 593 of the Companies Act by Mazars LLP as at 31 December 2017, based on the net asset values as at that date less any distributions to shareholders of the Predecessor company prior to the date of acquisition. The interim financial statements include all transactions performed on the life insurance policies as from 1 January 2018.
Each share class of the Company were first admitted to trading on the Specialist Fund Segment of the main market of the London Stock Exchange on 26 March 2018.
It is the intention of the Company to conduct its affairs so that it satisfies the conditions necessary for it to be approved by HM Revenue & Customs as an investment trust.
1.2 Nature of operations
The principal activities of Life Settlement Assets and its subsidiaries (together "the Group") (Note 4) are to support, manage and fund the acquisition of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the United States (Note 9).
Once acquired, the policies are the property of the Acheron Portfolio Trust, a grantor trust established in the Commonwealth of Massachusetts USA, the Lorenzo Tonti 2006 Trust, a trust established in the State of New York, the Avernus Portfolio Trust, a trust established under the laws of the State of Delaware, or Styx Portfolio Trust, a trust established in the State of Delaware. Class A Shares, Class B Shares, Class D Shares, and Class E Shares (respectively) are the exclusive beneficiaries of these trusts.
The trusts are managed by Acheron Capital Limited, a London-based company which is authorized and regulated by the Financial Conduct Authority of the United Kingdom (under reference number 443685).
1.2 General information and statement of compliance with IFRS
The Company is the Group's ultimate parent company.
The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Boards (IASB) as adopted by the European Union.
The consolidated financial statements for the period ended 30 June 2018 were approved and authorized for issue by the Board of Directors on 25 September 2018.
Note 2 IFRS accounting policies
2.1 Basis of preparation
The consolidated financial statements have been prepared using the accounting policies specified by those IFRS that are in effect at the end of the reporting period (30 June 2018), or which have been adopted early.
The present financial statements report on the activity for the period from inception on 16 August 2017 until 30 June 2018.
For the purpose of the cash flow statement, the acquisition by the Company of Net Assets from the Predecessor Company under the Acquisition agreement mentioned in Note 1.1 for a total amount of USD 133,723,937 and the allotment of 7,068,874 shares to the Predecessor Company is a non-cash transaction that is not shown in the cash flow statement, except for the net cash contribution of USD 18,883,524.
The significant accounting policies that have been applied in the preparation of these consolidated financial statements are summarized below.
2.2 Changes in accounting policy and disclosures
Standards and amendments to existing standards that are not yet effective and have not been early adopted by the Group
The following new standards and amendments have been published but are not effective for the Group's accounting period beginning on 16 August 2017. The Company does not expect the adoption of the following new standards, amended standards or interpretation to have a significant impact on the consolidated financial statements of Life Settlement Assets in future periods.
IFRS 16, "Leases" defines a lease as a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration. IFRS 16 requires lessees to recognise nearly all leases on the balance sheet which will reflect their right to use an asset for a period of time and the associated liability for payments. IFRS 16 will be effective for reporting periods beginning on or after 1 January 2019.
IFRS 17 "Insurance contracts"
Applies to insurance contracts, including reinsurance contracts issued by an entity; reinsurance contracts held by an entity; and investment contracts with discretionary participation, features issued by an entity that issues insurance contract. IFRS 17 will be effective for reporting periods beginning on or after 1 January 2021.
Note 3 Significant accounting policies
3.1 Basis of consolidation
The consolidated financial statements consolidate those of the parent Company and all of its subsidiary undertakings drawn up to 30 June 2018 (Note 4). Subsidiaries are entities over which the Group has control. The Group controls an entity when it has power over an entity, is exposed to, or has rights to, variable returns from its involvement with the entity, and has the ability to affect these returns through its power over the entity.
The year end for the Company and all subsidiaries' is 31 December.
All transactions and balances between the Group companies, including realized and unrealized gains and losses on transactions are eliminated. Where unrealized losses on intra-group asset sales are reversed on consolidation, the underlying asset is also tested for impairment from a Group perspective. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group.
There was no non-controlling interest (minority interest) at the year end.
3.2 Foreign currency translation
The consolidated financial statements are presented in United States Dollars (USD), which is also the functional currency of the Group.
(a) Interim/Annual accounts
Foreign currency transactions are translated into the functional currency of the Group, using the exchange rates prevailing at the date of the transaction (spot exchange rates). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items at year-end exchange rates are recognized in profit or loss.
(b) Consolidated accounts
All companies included in the consolidated accounts have their financial statements prepared in USD.
3.3 Segment reporting
Operating segments are reported in a manner consistent with the internal reporting used by the Group's management. The Group's management, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors that make strategic decisions.
Segment information:
The Group's management makes the strategic resource allocations on behalf of the Group. The Group's management has identified that the insurance portfolios or portfolio rights acquired can all be classified as life settlement business and all of which are located in the United States of America. As such, there is a single operating segment.
The asset allocation decisions are based on a single, integrated investment strategy, and the Group's performance is evaluated on an overall basis. The investment objective of the Group is medium-term capital growth. An analysis of expected maturities is given in Note 9.3 of the consolidated financial statements.
The internal reporting provided to the Management team for the Group's assets, liabilities and performance is prepared on a consistent basis with the measurement and recognition principles of IFRS.
All of the Group's income is from revenue generated on the life settlement portfolios in the USA. The life settlement portfolios are classified as non-current assets.
3.4 Life-settlement portfolios
Being the final and exclusive beneficiary of the Acheron Portfolio Trust, the Lorenzo Tonti 2006 Trust, the Avernus Portfolio Trust and the Styx Portfolio Trust, the Group reflects all the transactions performed on these life insurance portfolios in its own financial statements. Investments in transactions to support the acquisition of life settlement assets by the Trusts are considered as having been undertaken by the Company for its own account.
Insurance policies which are acquired are recognized initially at fair value (the transaction price). If a life insurance policy matures, is surrendered or is sold, the related purchase price is recognized as a cost of sale. Cash borrowed on life insurance policies is deducted from the value of the relevant policy.
The value of insurance contracts is usually recovered upon the death of the insured policyholder. However, the Company may from time-to-time decide to dispose of an individual life insurance contract.
Insurance portfolios are measured at fair value (Note 9).
3.5 Impairment of non-financial assets
Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
3.6 Financial instruments
Financial assets and financial liabilities are recognized when the Group becomes a party to the contractual provisions of the financial instrument. Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred.
A financial liability is derecognized when it is extinguished, discharged, canceled or expires.
Financial assets and financial liabilities are measured initially at fair value plus transaction costs, except for financial assets and financial liabilities carried at fair value through profit and loss, which are measured initially at fair value.
Financial assets and financial liabilities are measured subsequently as described below.
Financial assets
For the purpose of subsequent measurement, financial assets, other than those designated and effective as hedging instruments, are classified into the following categories upon initial recognition:
- loans and receivables;
- financial assets held at fair value through profit or loss.
The category determines subsequent measurement and whether any resulting income and expense is recognized in profit or loss or in other comprehensive income.
All financial assets, except for those held at fair value through profit and loss, are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied to each category of financial assets, which are described below.
All incomes and expenses relating to financial assets that are recognized in profit or loss are presented within "finance costs", "finance income" or "other financial items".
Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for those with maturities greater than 12 months after the balance sheet date.
Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default.
Financial assets held at fair value through profit or loss
Financial assets held at fair value through profit or loss include financial assets that are either classified as held for trading or that meet certain conditions and are designated at fair value through profit or loss upon initial recognition.
Assets in this category are measured at fair value, with gains or losses recognized in profit or loss. The fair values of derivative financial instruments are determined by reference to active market transactions or through using valuation techniques where no active market exists.
The Group has designated the life settlement portfolios as held at fair value through profit and loss.
The Group manages its assets in a way to enhance profits through optimizing the life settlement portfolios, minimizing the premiums payable on the life settlement portfolios, and collecting maturities in order to maximize the cash generated by the portfolio and to distribute such realized profit or available cash to its Shareholders.
Financial liabilities
The Group's financial liabilities are only constituted by trade and other payables.
Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.
3.7 Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held on call with banks and other short-term, highly liquid investments with original maturities of three months or fewer.
3.8 Tax expenses
In May 2018, the Company received a confirmation from HM Revenue & Custom as an approved investment trust for accounting period commencing on or after 26 March 2018, subject to the Company continuing to meet the eligible conditions at section 1158 Corporation Tax Act 2010 and the ongoing requirements in Chapter 3 Part 2 Investment Trust (Approved Company) (Tax) Regulations 2011(Statutory Instrument 2011/2999)
Tax expenses recognized in profit or loss comprise solely withholding taxes (Note 16).
The current income tax charge is calculated on the basis of the local tax laws enacted or substantively enacted at the balance sheet date in the countries where the Group companies operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions, where appropriate, on the basis of the amounts expected to be paid to the tax authorities.
Deferred income tax, if any, is recognized, using the liability method, on temporary differences arising between the tax bases of the Group's assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.
Due to the Company's status as an investment trust, and the intention to meet the conditions required to obtain approval under Section 1158 of the Corporation Act Tax 2010, the Company has not accounted any deferred tax on its losses.
In relation to the subsidiaries detailed in note 4, all of them being in liquidation, the Company has not accounted any deferred tax on their losses.
3.9 Equity, reserves and dividend payments
Share capital represents the nominal value of the Shares that have been issued.
Share premium includes any premiums received on issue of share capital, or by other means.
All transactions with owners of the Group are recorded separately within equity.
3.10 Provisions, contingent liabilities and contingent assets
Provisions are recognized when: the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and the amount of the obligation can be reliably estimated.
Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects the current market assessment of the time value of money and the risks specific to the obligation. The increase in the provision due to the passage of time is recognized as an interest expense.
3.11 Revenue and expenses recognition
3.11.1 Revenues
Revenue comprises the fair value of the consideration received in relation to maturities or to the surrender or sale (if any) of life settlement policies. The Group recognizes revenue when the amount of revenue can be reliably measured and it is probable that the future economic benefits will flow to the entity.
Maturities are recognized as revenue when the Group is formally aware of the maturity of a life insurance policy.
Net income from life settlement portfolios derives from the maturity or the sale of insurance policies less their acquisition value and the change in the valuation of the fair market value of the remaining policies.
3.11.2 Premiums
Premiums are expensed when paid. However, only the portion of the premiums that relates to the insurance coverage period up to 30 June of each financial period is recognized as an expense. The remaining amount is shown as premiums paid in advance on the balance sheet.
3.11.3 Interest income
Interest income is recognized on a proportional basis using the effective interest method.
3.12 Significant management judgement in applying accounting policies.
The preparation of these financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies.
The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements relate mainly to the valuation of the investment portfolios and when revenues may be accounted for.
Management also set criteria stating when a life insurance policy can be considered to have matured and when the benefit of a maturity can be attributed to the Group (Note 3.11.1).
For the preparation of the annual audited accounts, the value of the life settlement (LS) and HIV portfolios is set by an external actuary, Lewis & Ellis (L&E). L&E was also the external actuary of the predecessor company.
Using these values, Acheron Capital Ltd (the Investment manager of the trusts in which the policies of Class A, B, D and E are kept) resets its internal model at beginning of each year, if necessary. It then produces regular monthly valuations using its internal model. This was the case in 2018 to produce the mid-year numbers.
Note 4 Consolidated companies
The consolidated financial statements of the Group include Life Settlement Assets Plc as the parent Company and the following wholly owned subsidiaries:
- Acheron Portfolio Corporation Ltd, Ireland.
- Lorenzo Tonti Ltd, Ireland;
- Styx Limited, Ireland.
All subsidiary undertakings are included in the consolidation. The proportion of the voting rights in the subsidiary undertakings held by the parent Company does not differ from the proportion of ordinary shares held. The subsidiaries have not issued shares, other than ordinary shares.
The Company's subsidiaries do not carry out any life settlement business. They have been put into liquidation on 18 December 2017. The liquidation is expected to be completed before year end. The liquidation should have no significant impact on the NAV or the net equity of the Company
Note 5 Financial risk management
5.1 Financial risk factors
The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize the potential adverse effects on the Group's financial performance. Risk management is carried out by the Board of Directors.
Foreign Exchange Risk
Assets, income and most transactions are denominated in USD. Only part of the Company's current expenses is denominated in Euros and is paid as incurred. Consequently the Group believes that it does not have a significant foreign exchange risk.
Interest Rate Risk
Apart from cash, cash equivalents, the assets of the Group are mainly composed of portfolios of life settlement policies. Life settlement policies are uncorrelated with traditional capital markets. Changes in the level of interest rates (other than extraordinary moves) are not a major factor in the valuation of such assets. Mortality projection and Cost of insurance ("COI3) (premium projections) are the major factors that affects the valuation of the Group's assets.
As the Group has no significant interest-bearing assets, the Group's income and operating cash flows are not substantially dependent on changes in market interest rates.
Credit Risk
The primary credit risk faced by the Group relates to solvency of the insurance companies that underwrite the insurance policies, which are the main assets of the Group. It should be noted that in addition to the creditworthiness of the insurance company issuing the life insurance policy, most of the policies also benefit from legal guarantees at a state level in the event that the insurance company that issued the policy becomes insolvent.
Credit risk is also mitigated by owning life insurance policies issued by a wide range of insurance companies and through not having an excessive exposure to any one company.
Available cash is deposited with reputable banks.
Liquidity risk
Prudent liquidity risk management requires the Group to maintain sufficient cash, cash equivalents and marketable securities for the Group's day-to-day requirements.
A proportion of the Group's investments are in fractional life insurance policies. Fractional life insurance policies are where a number of different investors own interests in a single underlying life insurance policy.
There is a risk that other investors in a given life insurance policy may decide not to continue to pay the premiums associated with their interest and may allow their investment to lapse. In this situation the Group must retain sufficient additional liquidity to buy out the lapsing investors' fractional interests and to bear the associated increase in premium payments in order to ensure that the underlying life insurance policy does not lapse.
Management monitors cash and cash equivalents on an ongoing basis. This is carried out in accordance with the practice and limits set by the Board of Directors.
Despite the level of maturities during the reporting period, the Group did not face any cash flow problems. The Group is presently not dependent on borrowings to manage and finance its current business. All investments are financed by equity.
Risks associated with actuarial assumptions
Mortality tables are used in the valuation processes of the Group in order to simulate the cash flow expected from the Policies. Past mortality experience may not be an absolute accurate indicator of future mortality rates. Individuals with specific life expectancies may experience a lower mortality rate in the future than experienced by persons with the same traits in the past. Changes in the mortality tables may have an adverse effect on the Group's operations and the value of the Shares.
Individuals may live longer than expected by the Group when the respective policies were purchased. In this case, the value of the policy decreases. The Group will be required to pay additional life insurance premium payments on the policy until its maturity. This may result in delayed cash flow to the Group, which may have an adverse effect on the return on the Shares.
The Group often acquired policies by auction without having obtained all available information concerning such policies. The valuation leading to these acquisitions is thus, based on assumptions that may, in fact, be incorrect or may never be verified.
The valuation methods used by different actuaries may vary. The methods used by a actuary may thus produce different results for the same insured person from those used by other actuaries.
Advances in medical science and disease treatment, particularly those related to HIV and AIDS, may increase the life expectancy of individuals or viators. Although an actuary will attempt to account for such advances, one or more unexpected breakthroughs in medical treatment, or a cure for a previously incurable illness, could further increase the life expectancy of insured.
In some cases, the Group will depend on life expectancy estimate of doctors, disease specific medical mortality models or actuaries. From time to time, the Group may seek the opinion of any of such persons, or rely on such a model to determine life expectancies. The valuation is thus dependent on these estimations or mortality profiles accurately modeling life expectancies.
The valuation of the policies is inherently difficult due to a number of assumptions that have to be made in this process. Any change in one of these assumptions may result in substantially different values. While the Investment Manager and the Valuation Agent attempt to provide reasonable valuations for the policies held by the Trusts, there is no guarantee that these valuations will correspond to the realizable value of the policies.
A more detailed description of the key risks is on pages 11-13 and pages 15-30 of the Company's prospectus.
5.2 Capital risk management
The Group's objectives in managing capital are to safeguard the Group's ability to continue as a going concern and to maintain an optimal capital structure in order to minimize the Group's cost of capital.
In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to Shareholders, return capital to Shareholders or issue new Shares.
The Group had cash balances of USD 19,3 million. Reference is also made to the cash flow statement.
5.3 Fair value estimation
The fair value of life settlement portfolios (which are not traded in an active market) is determined by using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on the market conditions that exist at each balance sheet date.
Note 6 Financial instruments measured
at fair value
The life settlement portfolios have been designated as financial assets held through profit and loss as their performance is evaluated on a fair value basis.
Notes 9 presents the Group's financial assets and liabilities measured at fair value in accordance with the fair value hierarchy set out in IFRS 13. This hierarchy groups financial assets and liabilities into three levels based on the significant inputs used in measuring the fair value of the financial assets and liabilities.
The fair value hierarchy has the following levels:
- level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- level 2: inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- level 3: inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).
Life settlement portfolios are classified as level 3. At year-end, these portfolios were valued by the external actuaries using a computer model (Note 9).
The tables below provide an analysis of the financial instruments that are measured at fair value, grouped into levels 1 to 3 based on the degree to which the fair value is observable:
Level 1 Level 2 Level 3 Total
USD USD USD USD
Life settlement
portfolios - - 95 530 397 95 530 397
______ _______ _________ _________
- - 95 530 397 95 530 397
====== ======= ========= =========
Note 7 Premiums paid in advance
Premiums paid in advance consist of the amount of premiums paid as of 30 June 2018 that relate to the period following the balance sheet date.
Note 8 Cash and cash equivalents
As at 30.06.2018, cash and cash equivalents consist solely of cash held on deposit and on current accounts with banks.
Note 9 financial assets held at fair value through profit
or loss: Life-settlement portfolios
Details of portfolios are as follows:
30.06.2018
USD
Acquisition value, net of maturities
and disposals 39 453 638
Loans on policies -22 343 093
Cumulative gain in fair value 84 982 715
(________________)
102 093 260
==========
Development of the acquisition value:
30.06.2018
USD
Opening balance (1) 40 250 409
Additions 298 061
Matured policies/disposal/other -1 094 831
(______________)
Balance as at 30 June 39 453 638
=========
(1) The opening balance refers to the Acquisition Agreement (Note 1.1)
Distribution of the portfolio by class of Shares and by type of risk:
Class Class B Class D Class E
A
USD USD USD USD
25 824
Life Settlements portfolio 353 12 819 849 7 352 953 4 501 867
41 744
HIV portfolio 823 2 338 848 947 705
(______________) (______________) (_____________) (_____________)
67 569
Balance as at 30.06.2018 176 12 819 849 9 691 801 5 449 572
========= ========= ======== ========
Fair market value reflects the view of Acheron Capital Ltd (the Investment manager of the trusts in which the policies of Class A, B, D and E are kept). Acheron Capital has set up an internal actuarial model to value the policies. It produces regular monthly valuations.
9.1 Main assumptions used to determine the fair value
a) Mortality/Life expectancy
Lewis & Ellis Inc, ("L&E") has built its own proprietary general population mortality table. It has done so by utilizing insurance industry and other data available, including the underlying data that went into the construction of the Valuation Basic Table, which has been commonly utilized within the life settlement industry. The mortality is adjusted for several factors, such as demographic shifts in the population, improvements in mortality, pharmaceutical advances and volatility in the mortality experienced as measured against the baseline curves chosen for valuation. The table includes an assumption of continuing mortality improvement each year. The retained table is used in connection with each insured age, sex and smoking status.
L&E is also considering the most recent life expectancy reports, when available. Life expectancy reports are medical opinions from specialized companies, based on the latest medical updates of each individual, giving their specific mortality profile and life expectancy. When life expectancy reports from more than one external provider are available, L&E uses an average. When only 'stale' life expectancy reports are available, the life expectancy is used but adjusted materially upwards using a formula dependent upon the medical underwriter that issued the report. L&E uses the retained or computed life expectancy with the adjusted mortality table to derive a probability of death for each insured for every month over the next 35 years.
The Actual to Expected ratio is a measure of how well the model has behaved compared to experience. This ratio was computed for the life settlement portfolios underlying Class A and Class B Shares. A key issue with this exercise is the concentration of all Share Classes in certain policies with larger face values. This generates an imbedded volatility in the actual maturity outcomes compared to statistical projections. To circumvent this imbalance, the actuaries have calculated the Actual to Expected ratio to measure the model's performance while limiting the maximum exposure of the portfolio to any life insurance policy.
On this basis, the Investment Manager estimated that the Actual to Expected ratio based on what was provided to APC until Dec 2017 (both in terms of maturities from services and projections by L&E) for the previous Class A of APC that become Class A of Life Settlement Assets, was about 108% over the last four years, and close to 165% for the elderly insureds and 89% for HIV in 2017. Similarly, it was about 105% for the period 2011-2017, and 149% in 2017 for Class B.
For the first half year of 2018, the estimated Actual to Expected ratio for LSA Class A, based on the L&E projection for the previous APC Class A has an estimated ratio for life settlement policies of 36% and 132% for HIV. Life Settlement is increasingly susceptible to a few large policies, making A/E on short period most volatile, as illustrated by the 2017 and 2018 H1 calculations.
In the case of specific diseases, such as HIV, L&E has developed an internal specific mortality adjustment that is applied to the general population table it has built. In 2015, L&E updated its HIV model with a focus on the most advanced age mortality. The updated L&E model continues to allow for a yearly increase of the mortality for each additional year that a patient has suffered from HIV, but at a reduced pace for the senior over 65. It is thus an age-based and time-based disease model, with a specifically computed over-mortality applied to each affected individual.
L&E's HIV model continue to be adjusted to fit the observed data over the past years, so that it is by nature consistent with observed experience. One of the modelling challenges is the speculative nature of HIV at the most advance ages given the lack of a population to test any hypothesis on. Another is incurred but not reported maturities (IBNR), particularly with one servicer.
On the ABC portfolio (representing less than 5% of the value of the portfolios), the Board has come to the conclusion that additional monitoring is required to ensure maturities are captured in timely basis.
b) Projected Premiums
Whenever an illustration is available, L&E uses this data for premium projections. An illustration is an official document from the insurance company that specifies what premiums are due to be paid in the following years for a life insurance policy. An illustration can be used to compute what is the likely minimum payment that can be made for each year until the life insurance policy expires. The process of moving from paying a fixed premium to paying the minimum contractual premium is known as optimization.
Premium projection has been more challenging given the unilateral increases in COI made by a few insurance companies. Whenever information on such COI increases has been available, it has been directly incorporated.
When no illustration is available or is deemed unsuitable to be used, for instance because it does not project sufficiently into the future, L&E takes the last observed premium payment and applies an annual increase of 8% per year.
c) Discount rate
The discount rate reflects the time value of money and a risk component. The risk component reflects the uncertainties attached to each individual life insurance policy, such as its mortality risk, premium risk and counterparty party risk.
HIV/AIDS Portfolios
In determining the discount rate for the HIV/AIDS portfolios, it should be noted that there is no readily observable market for these policies. Because of this, L&E used their experience in the life settlement market, on the basis that life settlement portfolios are comparable assets.
A discount rate of 11% is used for the HIV/AIDS portfolios which is consistent with past valuations. To assess the discount rate, the following reasoning has been used, starting with a base rate:
-- Assuming a sufficiently large portfolio, the base rate must be consistent with the discount rate determined for a situation where the mortality assumptions and policy specifics are well-defined. Specifically, the mortality is defined so that actual experience is expected to track well with the defined mortality assumptions.
The base rate is increased for the following criteria:
-- Mortality experience: although the actual-to-expected (A/E) mortality ratio over the last seven years is about 100%, the A/E ratio over the last three years is about 90%;
-- Mortality assumptions: this criteria has been lowered in relation with the more conservative mortality assumptions beyond age 65;
-- Policy modeling: this parameter reflects some portfolio-wide assumptions that are made to define the premium schedules;
-- An additional adjustment has been added to the base rate to account for items not mentioned above.
Life Settlement Portfolios (Non-HIV/Non-AIDS)
In determining the discount rate for the life settlement portfolios, it has been considered that complete policy information was not always available. For most life settlement valuations, the premium schedules and at least two recent life expectancy opinions are provided. For these valuations, premium schedules were estimated for some of the policies and mortality assumptions were developed using older life expectancy opinions or no life expectancy opinions at all for most of the policies. Given this, the discount rate is subjective but based on the actuaries experience in the life settlement market.
In determining the portfolio values, a portfolio-wide discount rate assumption equal to 12% for non HIV and 11% for HIV has been used which is consistent with last year. For the discount rate this year also, some buy/sale observations were considered where the effective discount rate was between 12 and 14%, although effective discount rates in the competitive market were probably between 10 and 12%. Other well documented portfolios have been valued at between 7% and 11% in their financial statements. It is expected that the actual-to-expected mortality ratios for most of these portfolios are lower than 70%, materially below the rates of experience by our portfolios. Given this, discount rates of 12% and 11% respectively have been maintained for the current year, considering the actual performance compared to other portfolios in the market, and considering a risk premium related to the quality of the documentation.
9.2 Precision and changes in actuarial parameters/data
As per the market standard, the servicing, management and holding entities expenses are not taken into account in deriving the valuation of the life settlement portfolios. The actuaries, following industry standards, are solely discounting the probabilistic projections of death benefits minus premiums, policy loans and interest thereon.
9.3 Sensitivity analysis
L&E conducted various sensitivity analyses which are summarized as follows:
a) Class A
a.1) Discount rate sensitivity
Discount rate -
non HIV portfolio 10% 12% 14% 16%
25 824 24 446 23 536
Value of portfolio 26 614 934 353 217 859
% of total face
amount 26.4% 25.2% 24.2% 23.3%
Discount rate -
HIV portfolio 9% 11% 13% 15%
47 154 41 744 37 656 34 483
Value of portfolio 129 823 487 044
% of total face
amount 13.0% 11.5% 10.4% 9.5%
a.2) Premium assumption sensitivity
Value based on 12% discount rate Annual premium increase
- non HIV portfolio at
8% 9%
25 366
Value of portfolio 25 824 353 517
% of total face amount 25.2% 25.1%
Value based on 11% discount rate Annual premium increase
- HIV portfolio at
8% 9%
40 528
Value of portfolio 41 744 823 316
% of total face amount 11.5% 11.2%
a.3) Mortality sensitivity
Value based on 12% discount rate - USD % of face
non HIV portfolio amount
25 824
Value of portfolio as reported 353 25.2%
Value at 90% of current mortality assumption 22 943
(*) 575 22.7%
Value at 80% of current mortality assumption 20 261 162 20.1%
(*) Assumption that mortality is only 90% of expected mortality.
Value based on 11% discount rate - USD % of face
HIV portfolio amount
41 744
Value of portfolio as reported 823 11.5%
35 217
Value at 90% of current mortality assumption 392 9.7%
28 650
Value at 80% of current mortality assumption 834 7.9%
b) Class B
b.1) Discount rate sensitivity
Discount rate -
non HIV portfolio 11% 12% 13% 14%
12 819
Value of portfolio 13 212 428 849 12,441,043 12 090 218
% of total face
amount 22.1% 21.5% 20.8% 20.3%
In class B, the portfolio comprises one HIV Policy with amount of USD 5 446.
b.2) Premium assumption sensitivity
Value based on 12% discount rate Annual premium increase
(non HIV portfolio) at
8% 9%
Value of portfolio 12 819 849 12 797 935
% of total face amount 21.5% 21.4%
b.3) Mortality sensitivity
Value based on 12% discount rate (non USD % of face
HIV portfolio) amount
Value of portfolio as reported 12 819 849 21.5%
11 406
Value at 90% of current mortality assumption 085 19.1%
Value at 80% of current mortality assumption 9 959 680 16.7%
c) Class D
c.1) Discount rate sensitivity
Discount rate - non HIV portfolio 10% 12% 14% 16% Value of portfolio 7 687 935 7 352 953 7 058 324 6 795 659 % of total face amount 28.9% 27.6% 26.5% 25.5% Discount rate - HIV portfolio 9% 11% 13% 15% Value of portfolio 2 744 485 2 338 848 2 028 664 1,784,884 % of total face amount 16.7% 14.2% 12.3% 10.8%
c.2) Premium assumption sensitivity
Value based on 12% discount rate Annual premium increase
- non HIV portfolio at
8% 9%
Value of portfolio 7 352 953 7 324 210
% of total face amount 27.6% 27.5%
Value based on 11% discount rate Annual premium increase
- HIV portfolio at
8% 9%
Value of portfolio 2 338 848 2 231 216
% of total face amount 14.2% 13.5%
c.3) Mortality sensitivity
Value based on 12% discount rate - USD % of face non HIV portfolio amount Value of portfolio as reported 7 352 953 27.6% Value at 90% of current mortality assumption 6 548 890 24.6% Value at 80% of current mortality assumption 5 689 385 21.4% Value based on 11% discount rate - USD % of face HIV portfolio amount Value of portfolio as reported 2 338 848 14.2% Value at 90% of current mortality assumption 1 986 473 12.1% Value at 80% of current mortality assumption 1 627 075 9.9%
d) Class E
d.1) Discount rate sensitivity
Discount rate - non HIV portfolio 10% 12% 14% 16% Value of portfolio 4 687 930 4 501 867 4 335 990 4 187 537 % of total face amount 29.3% 28.1% 27.1% 26.1% Discount rate - HIV portfolio 9% 11% 13% 15% Value of portfolio 1 099 074 947 705 830 178 736 708 % of total face amount 17.3% 14.9% 13.1% 11.6%
d.2) Premium assumption sensitivity
Value based on 12% discount rate Annual premium increase
- non HIV portfolio at
8% 9%
Value of portfolio 4 501 867 4 482 094
% of total face amount 28.1% 28.0%
Value based on 11% discount rate Annual premium increase
- HIV portfolio at
8% 9%
Value of portfolio 947 705 906 644
% of total face amount 14.9% 14.3%
d.3) Mortality sensitivity
Value based on 12% discount rate - USD % of face non HIV portfolio amount Value of portfolio as reported 4 501 867 28.1% Value at 90% of current mortality assumption 4 026 663 25.1% Value at 80% of current mortality assumption 3 524 793 22.0% Value based on 11% discount rate - USD % of face HIV portfolio amount Value of portfolio as reported 947 705 14.9% Value at 90% of current mortality assumption 800 273 12.6% Value at 80% of current mortality assumption 656 271 10.3%
Distribution of face value by insurance company at 30 June 2018
Class A: companies assuring 2018 2018 2017 2017
at least
Number Total Number Total
% %
Over 10 % of the nominal
face value 1 12.0 1 11.5
5 % to 10 % 1 6.2 1 6.0
2 % to 5 % 12 35.5 12 34.7
0 % to 2 % 314 46.3 315 47.8
Class B: companies assuring 2018 2018 2017 2017
at least
Number Total Number Total
% %
Over 10 % of the nominal
face value 2 24.0 1 11.6
5 % to 10 % 5 30.4 5 37.1
2 % to 5 % 9 24.3 7 20.9
0 % to 2 % 29 21.3 37 30.4
Class D: companies assuring 2018 2018 2017 2017
at least
Number Total Number Total
% %
Over 10 % of the nominal - - - -
face value
5 % to 10 % 4 27.8 4 27.7
2 % to 5 % 11 34.9 8 25.2
0 % to 2 % 101 37.2 121 47.1
Class E: companies assuring 2018 2018 2017 2017
at least
Number Total Number Total
% %
Over 10 % of the nominal
face value 1 13.0 - -
5 % to 10 % 5 35.0 6 41.6
2 % to 5 % 8 22.4 9 27.5
0 % to 2 % 70 29.6 80 30.9
Note 10 Share Capital
At the end of the period, the Company's share capital amounts to USD 710 689, and is represented by 71 068 874 shares of USD 0.01 each. The development of the share capital is as follows:
A Shares B Shares D Shares E Shares Redeemable Total
preference
shares
USD USD USD USD USD USD
Balance 16 August
2017
Movements for the
period:
* Incorporation - (-) (-) - 66 988 66 988
* Redemption -66 988 -66 988
* Capital increase 454 469 145 961 92 926 17 333 710 689
(___________) (___________) (_________) (_________) (_______) (___________)
Balance as 30 June
2018 454 469 145 961 92 926 17 333 - 710 689
(===========) (===========) (=========) (=========) (=======) (===========)
At incorporation, the Company issued 1 ordinary A share of $.0.01 and 50,000 of GBP1 preference shares at par. Redeemable Preference shares have been cancelled on 26 March 2018.
The share capital has been increased on 26 March 2018, by the issue of:
- 45 446 946 A Shares with a par value of USD 0.01, in addition to a share premium of USD 95 005 654
- 14 596 098 B Shares with a par value of USD 0.01, in addition to a share premium of USD 18 459 571
- 9 292 561 D Shares with a par value of USD 0.01, in addition to a share premium of USD 11 567 985
- 1 733 269 E Shares with a par value of USD 0.01, in addition to a share premium of USD 7 980 276.
As at 30 June 2018, the share capital is composed of 45 446 946 Class A shares, 14 596 098 Class B shares, 9 292 561 D Shares, and 1 733 269 Class E shares.
Class A, Class B, Class D and Class E Shares relate to specific investments determined by the Board of Directors or as the case may be, by a general meeting of Shareholders. Each investment is undertaken for the exclusive benefit and risk of the relevant class of Shares.
Note 11 other liabilities
Details of the caption are as 30.06.2018
follows:
USD
Audit and accounting fees 290 915
Legal fees 328 776
Actuarial fees 141 253
Services fees 105 912
Director and audit committee fees 196 845
Administrative Management fees 82 005
Travelling expenses 7 956
(_____________)
1 153 662
(=============)
Note 12 NET Income from life-settlement portfolios
Details of the income received from the life-settlement portfolios:
30.06.2018
USD
Maturities 20 278 400
Acquisition cost of maturities -1 094 831
Incurred premiums -11 285 217
Fair value adjustments -8 623 451
(____________)
-725 099
(============)
The amount of premiums incurred during the year is reflected as a deduction of income from life settlement portfolio. The amount of premiums paid in advance amounted to USD 12 887 407 as at 30 June 2018.
Note 13 Operating expenses
30.06.2018
USD
Acheron Capital management fees 1 078 249
Portfolio servicing fees 1 278 024
Audit fees 60 633
Legal and financial advisors fees 1 175 128
Administration, including accounting 205 630
Actuarial fees 56 348
Directors fees, Directors insurance
expenses 107 760
Other expenses 206 101
(_____________)
4 167 871
(=============)
Note 14 Other income from matured
policies
Details of other income from matured policies are as follows:
30.06.2018
USD
Dividend 201 882
Interest 72 847
(___________)
274 729
(===========)
Note 15 Interest expenses
Other interest payable and similar charges amount to USD 632 595, and is mainly composed of interest on policy loans of USD 609 722 (Note 9)
Note 16 Tax expenses
16.1 Withholding tax on matured policies
In conformity with the taxation treaty between the United States of America and the United Kingdom withholding tax on matured policies is not due if at least 6% of the average capital stock of the main class of Shares is traded during the previous year (or in the Company's case during the first year) on a recognized stock exchange.
The Company is however subject to US income tax on some income from life policies (i.e. dividend and interest income).
16.2 Income tax
Neither the Company, nor its subsidiaries (Note 4) incurred income taxes. Reference is made to Note 3.8.
Note 17 Tax liabilities
Tax provision as at year-end is as follows:
30.06.2018
USD
Tax liabilities as accrued by the
Predecessor company 745 310
=======
Note 18 Transactions with related
parties
30.06.2018
USD
Per profit and loss:
Directors' fees (paid or accrued) 63 253
Acheron Capital Ltd management fees
(note 13) 1 078 249
Compagnie Européenne de Révision
S.à r.l. as Administrator 110 224
Per balance sheet:
Directors' fees 34 325
Compagnie Européenne de Révision
S.à r.l. 3 428
12 941
Shares held by related parties 017
The Company and Compagnie Européenne de Révision Sàrl have one common Director. All transactions with related parties are undertaken at arm's length.
Note 19 Net consolidated profit per
share
As stated in Note 10, the capital of the Company is composed of 45 446 946 A Shares, 14 596 098 B Shares, 9 292 561 D Shares, and 1 733 269 E Shares. All Shares are fully paid. Neither unpaid shares nor any kind of option are outstanding, so that the basic profit per share is equivalent to the diluted profit per share.
As the different classes of Shares have specific rights in relation to their investments, the net consolidated profit per share is given for each Share Class:
2018 Class A Class Class Class
USD B D E
USD USD USD
Profit/loss per share:
Basic and diluted profit/loss
per share -0.133 -0.087 -0.186 -0.110
-3 204
Numerator 579 -676 908 -918 231 -100 929
Denominator (weighted average
number of shares over the 24 101 7 741 -4 928
period) 458 577 651 -919 303
Note 20 Net consolidated assets per
class of shares
The consolidated net assets for each class of Shares are shown below. Net assets for each class of Shares can be reconciled as follows:
30.06.2018
USD
Consolidated net assets Class
A Shares 92 255 545
Consolidated net assets Class
B Shares 17 928 624
Consolidated net assets Class
D Shares 10 742 680
Consolidated net assets Class
E Shares 7 896 679
__________
128 499 691
==========
Note 21 Management fees and Performance
fees
The Investment Manager (Note 1.1) is entitled to a management fee payable by the Trusts at an annual rate of no more than 1.5% of the Net Asset Value for classes A, B and D, and 2% for class E.
The Performance fee in respect of the Trusts shall be an amount equal to 25% of the sum of the distributions made to the holders of the shares in the capital of the Company corresponding to the Trusts, in excess of the Performance Hurdle (assessed at the time of each distribution).
The "Performance Hurdle" is met when (from time to time) the aggregate distributions (in excess of the Catch-Up Amount) made to the holders of the corresponding Ordinary Shares compounded at 3% per annum for classes A and B, and 5% for classes D and E (from the date of each distribution) equal the aggregate investment made by the Ordinary Shares in the Company (from time to time) compounded at 3% and 5% respectively.
The "Catch-Up Amount" is an amount equal to the distributions that would have been required to be made to the Predecessor Company Shareholders of the corresponding share class in order for the Accrued Performance Distributions (less, where applicable, any clawback of such Accrued Performance Distributions) to be paid (determined as at 31 December 2017), reduced by an amount equal to any distributions paid to Predecessor Company Shareholders of the relevant share class prior to the Acquisition.
Note 22 FATCA
The Company is registered with the internal Revenue Service (IRS) as a Foreign Financial Institution for the purposes of the Foreign Tax Compliance ACT (FATCA).
The Company's Global Intermediary Identification Number (GIIN) is ZCX23Y.99999.SL.826
Note 23 Common Reporting Standards
("CRS")
The CRS legislation, adopted by the Organisation for Economic Co-operation and Development, requires the Company to provide personal information to HM Revenue & Custom on certain investors who purchase shares in investment trusts. This information will have to be provided annually to the local tax authority of the tax residencies of a number of non-UK based certificated shareholders and corporate entities.
Note 24 Post balance sheet event
No event having an impact or influence on the present financial statements occurred after the balance sheet date.
Note 25 Additional information
Additional information of exhibits I to IV do not form part of the financial statements.
_________________________________________________
EXHIBIT I (unaudited)
Life Settlement Assets Plc
Class A
Net assets
_____________________________________________________
Notes 30/06/2018
USD
Non-current assets
Financial assets at fair value through
profit and loss
- Life settlement investments 67 569 176
Maturities Receivables 3 809 626
71 378 802
Current assets
Premiums paid in advance 8 107 548
Other receivables and prepayments 237 982
Cash and cash equivalents 12 833 683
Intercompany receivables 1 713 219
22 892 432
Current liabilities
Trade and other payables 882 027
Other liabilities 624 497
Tax liabilities 509 165
2 015 689
Net assets 20 92 255 545
===========
EXHIBIT I/1 (unaudited)
Life Settlement Assets Plc
CLASS A
Interim consolidated statement of profit or loss and other
comprehensive income
for the period ended 30 June 2018
_____________________________________________________
30/06/2018
USD
Income from life-settlement portfolio
Maturities 13 698 530
Acquisition cost of maturities - 651 903
Premiums paid -7 251 357
Fair value adjustments -5 654 313
___________
Net income from life-settlement portfolio 140 957
Other operating income 54 322
Operating expenses -2 993 649
Finance income
Interest income 4 952
Other income from matured policies 260 891
___________
265 844
Finance costs
Interest expenses - 620 645
Net foreign exchange loss - 51 212
___________
- 671 857
Profit (Loss) before tax -3 204 383
Income tax expenses - 197
___________
Profit (Loss) for the period -3 204 579
============
Other comprehensive income -
Total comprehensive income for the period -3 204 579
============
Total comprehensive income attributable to the
owners of the Company -3 204 579
============
EXHIBIT I/2 (unaudited)
Life Settlement Assets Plc
Class A
Interim consolitated cash flow statement for the period
ended 30 June 2018
_____________________________________________________
30/06/2018
USD
Cash flow from operating activities
-3 204
Profit (Loss) for the period 579
Non cash adjustments:
- non cash movement on portfolios 5 458 993
Cash flows from (used) in operations before working
capital changes 2 254 414
Changes in premiums paid in advance 1 087 031
Changes in other receivables and prepayments - 201 501
-5 470
Changes in trade and other payables 706
Changes in tax payables - 11 785
-2 342
Net cash flows from (used) in operating activities 547
Cash flow from investing activities
Net investment in life-settlement portfolios 450 903
Net cash flows from (used) in investing activities 450 903
Cash flow from financing activities
14 880
Cash proceeds from issuing shares 399
Cash on policies - 155 072
14 725
Net cash flows from (used) financing activities 326
12 833
NET CHANGES IN CASH AND CASH EQUIVALENTS 683
Cash and cash equivalents
At beginning of the period -
12 833
At the end of the period 683
==============
EXHIBIT II (unaudited)
Life Settlement Assets Plc
Class B
Net assets
_____________________________________________________
Notes 30/06/2018
USD
Non-current assets
Financial assets at fair value through
profit and loss - Life settlement
investments 12 819 849
Maturities Receivables 557 901
13 377 750
Current assets
Premiums paid in advance 2 004 833
Other receivables and prepayments 10 092
Cash and cash equivalents 3 601 459
5 616 384
Current liabilities
Trade and other payables 348 132
Other liabilities 159 551
Tax liabilities 101 516
Intercompany payables 456 310
1 065 510
Net assets 20 17 928 624
===========
EXHIBIT II/1 (unaudited)
Life Settlement Assets Plc
CLASS B
Interim consolidated statement of profit or loss and
other comprehensive income
_____________________________________________________
30/06/2018
USD
Income from life-settlement portfolio
Maturities 2 988 505
Acquisition cost of maturities - 183 107
Premiums paid -2 143 828
Fair value adjustments - 936 937
___________
Net income from life-settlement portfolio - 275 366
Other operating income 7 261
Operating expenses - 407 735
Finance income
Interest income 724
Other income from matured policies 1 531
___________
2 254
Finance costs
Interest expenses - 3 175
Net foreign exchange loss - 147
___________
- 3 322
Profit (Loss) before tax - 676 908
Income tax expenses -
___________
Profit (Loss) for the period - 676 908
============
Other comprehensive income -
Total comprehensive income for the period - 676 908
============
Total comprehensive income attributable to
the owners of the Company - 676 908
============
EXHIBIT II/2 (unaudited)
ACHERON PORTFOLIO CORPORATION (Luxembourg)
Class B
Interim consolitated cash flow statement for the period
ended 30 June 2018
_____________________________________________________
30/06/2018
USD
Cash flow from operating activities
Profit (Loss) for the period - 676 908
Non cash adjustments:
- non cash movement on portfolios 1 116 130
Cash flows from (used) in operations before working
capital changes 439 222
Changes in premiums paid in advance - 315 411
Changes in other receivables and prepayments - 10 092
Changes in trade and other payables 359 889
Changes in tax payables -
Net cash flows from (used) in operating activities 473 608
Cash flow from investing activities
Net investment in life-settlement portfolios 1 229
Net cash flows from (used) in investing activities 1 229
Cash flow from financing activities
Cash proceeds from issuing shares 3 126 622
Cash on policies -
Net cash flows from (used) financing activities 3 126 622
NET CHANGES IN CASH AND CASH EQUIVALENTS 3 601 459
Cash and cash equivalents
At beginning of the period -
At the end of the period 3 601 459
===========
EXHIBIT III (unaudited)
Life Settlement Assets Plc
Class D
Net assets
_____________________________________________________
Notes 30/06/2018
USD
Non-current assets
Financial assets at fair value through
profit and loss - Life settlement
investments 9 691 800
Maturities Receivables 564 002
10 255 802
Current assets
Premiums paid in advance 1 713 584
Other receivables and prepayments 10 092
Cash and cash equivalents 1 151 246
Intercompany receivables -
2 874 922
Current liabilities
Trade and other payables 1 727 865
Other liabilities 178 348
Tax liabilities 77 568
Intercompany payables 404 264
2 388 045
Net assets 20 10 742 680
===========
Life Settlement Assets Plc
CLASS D
Interim consolidated statement of profit or loss and other
comprehensive income
_____________________________________________________
30/06/2018
USD
Income from life-settlement portfolio
Maturities 1 747 326
Acquisition cost of maturities - 123 469
Premiums paid -1 204 950
Fair value adjustments -1 151 920
__________
Net income from life-settlement portfolio - 733 013
Other operating income 272 244
Operating expenses - 461 658
Finance income
Interest income 1 939
Other income from matured policies 7 731
__________
9 669
Finance costs
Interest expenses - 5 241
Net foreign exchange loss - 233
__________
- 5 474
Profit (Loss) before tax - 918 231
Income tax expenses -
__________
Profit (Loss) for the period - 918 231
===========
Other comprehensive income -
Total comprehensive income for the period - 918 231
===========
Total comprehensive income attributable to the
owners of the Company - 918 231
===========
EXHIBIT III/2 (unaudited)
Life Settlement Assets Plc
Class D
Interim consolitated cash flow statement for the period ended
30 June 2018
_____________________________________________________
30/06/2018
USD
Cash flow from operating activities
Profit (Loss) for the period - 918 231
Non cash adjustments:
- non cash movement on portfolios 1 263 828
Cash flows from (used) in operations before working
capital changes 345 597
Changes in premiums paid in advance - 266 313
Changes in other receivables and prepayments - 10 092
Changes in trade and other payables - 74 848
Changes in tax payables -
Net cash flows from (used) in operating activities - 5 656
Cash flow from investing activities
Net investments in life-settlement portfolios - 4 951
Net cash flows from (used) in investing activities - 4 951
Cash flow from financing activities
Cash proceeds from issuing shares 1 161 853
Cash on policies -
Net cash flows from (used) financing activities 1 161 853
NET CHANGES IN CASH AND CASH EQUIVALENTS 1 151 246
Cash and cash equivalents
At beginning of the period -
At the end of the period 1 151 246
===========
EXHIBIT IV (unaudited)
Life Settlement Assets Plc
Class E
Net assets
_____________________________________________________
Notes 30/06/2018
USD
Non-current assets
Financial assets at fair value through
profit and loss - Life settlement investments 5 449 572
Maturities Receivables 1 631 335
7 080 907
Current assets
Premiums paid in advance 1 061 443
Other receivables and prepayments 10 092
Cash and cash equivalents 1 736 654
Intercompany receivables -
2 808 190
Current liabilities
Trade and other payables 891 446
Other liabilities 191 265
Tax liabilities 57 061
Intercompany payables 852 644
1 992 417
Net assets 20 7 896 679
EXHIBIT IV/1 (unaudited)
Life Settlement Assets Plc
CLASS E
Interim consolidated statement of profit or loss and other
comprehensive income
_____________________________________________________
30/06/2018
USD
Income from life-settlement portfolio
Maturities 1 844 040
Acquisition cost of maturities - 136 352
Premiums paid - 685 083
Fair value adjustments - 880 282
___________
Net income from life-settlement portfolio 142 323
Other operating income 60 730
Operating expenses - 304 830
Finance income
Interest income 15
Other income from matured policies 4 577
___________
4 592
Finance costs
Interest expenses - 3 534
Net foreign exchange loss - 210
___________
- 3 744
Profit (Loss) before tax - 100 929
Income tax expenses -
___________
Profit (Loss) for the period - 100 929
============
Other comprehensive income -
Total comprehensive income for the period - 100 929
============
Total comprehensive income attributable to
the owners of the Company - 100 929
============
EXHIBIT IV/2 (unaudited)
Life Settlement Assets Plc
Class E
Interim consolitated cash flow statement for the period ended
30 June 2018
_____________________________________________________
30/06/2018
USD
Cash flow from operating activities
Profit (Loss) for the period - 100 929
Non cash adjustments:
- non cash movement on portfolios 1 017 718
Cash flows from (used) in operations before working
capital changes 916 789
Changes in premiums paid in advance 495 729
Changes in other receivables and prepayments - 10 092
Changes in trade and other payables 624 204
Changes in tax payables -
Net cash flows from (used) in operating activities 2 026 629
Cash flow from investing activities
Net investments in life-settlement portfolios - 4 625
Net cash flows from (used) in investing activities - 4 625
Cash flow from financing activities
Cash proceeds from issuing shares - 285 350
Cash on policies -
Net cash flows from (used) financing activities - 285 350
NET CHANGES IN CASH AND CASH EQUIVALENTS 1 736 654
Cash and cash equivalents
At beginning of the period -
At the end of the period 1 736 654
==============
Life Settlement Assets Plc
Directors' Responsibility Statement
The Disclosure and Transparency Rules (DTR) of the UK Listing Authority require the Directors to confirm their responsibilities in relation to the preparation and publication of the Interim Management Report and Financial Statements.
The Directors confirm to the best of their knowledge that (i) the financial statements contained within the Interim financial report give a true and fair view of the assets, liabilities, financial position and profit and loss of the Company in accordance with IFRS, and the report has been prepared in accordance with IAS 34 "Interim Financial Reporting" and (ii) the Interim Management Report together with the Chairman's Statement and Investment Manager's Report include a fair review of the information required by 4.2.7R and 4.2.8R of the FCA's Disclosure and Transparency Rules.
This Interim report has not been audited or reviewed by the Company's Auditor. The Interim Financial Report was approved by the Board on 25 September 2018 and the above responsibility statement was signed on its behalf by the Chairman.
Jean Medernach
For and on behalf of the Board
27 September 2018
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IR FKFDKPBKDKCB
(END) Dow Jones Newswires
September 28, 2018 11:10 ET (15:10 GMT)
1 Year Life Settlement Assets Chart |
1 Month Life Settlement Assets Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
